Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -24.12% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-24.12%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+42.58%
vs the sector median at left
SpyGlass Pharma, Inc. Common Stock
Market Cap
$846.20M
Return on Equity (ROE)
-24.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$852.92M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
Market Cap
$851.61M
Return on Equity (ROE)
N/A
TTM Avg
-5137.85%
3Y Avg
-2593.82%
5Y Avg
-1731.57%
Market Cap
$837.21M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$835.14M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$857.60M
Return on Equity (ROE)
-8.03%
TTM Avg
-14.58%
3Y Avg
-29.27%
5Y Avg
-30.82%
Market Cap
$859.63M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$827.90M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$869.18M
Return on Equity (ROE)
-167.25%
TTM Avg
-94.03%
3Y Avg
-58.96%
5Y Avg
-58.96%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $846.20M | -24.12% | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $852.92M | -59.07% | -63.84% | -29.19% | -3.25% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $851.61M | N/A | -5137.85% | -2593.82% | -1731.57% |
| Beta Bionics, Inc. (BBNX)vs › | $837.21M | -28.46% | -48.75% | -33.66% | -33.66% |
| Alumis Inc. (ALMS)vs › | $835.14M | -97.08% | -96.94% | -22.72% | -22.72% |
| SI-BONE, Inc. (SIBN)vs › | $857.60M | -8.03% | -14.58% | -29.27% | -30.82% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $859.63M | 75.67% | 312.76% | 285.83% | 166.15% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $827.90M | -33.06% | -24.59% | -41.17% | -18.72% |
| SL Science Holding Ltd (SLBT)vs › | $869.18M | -167.25% | -94.03% | -58.96% | -58.96% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $879.93M | N/A | 30.44% | 30.44% | 30.44% |
ROE
-24.1%
ROA
-23.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -24.12% |
